Compugen Ltd

Compugen is a clinical-stage therapeutic discovery and development company that uses Unigen, its AI/ML-powered computational discovery platform, to identify novel drug targets and develop cancer immunotherapy treatments. The company's pipeline consists of three key programs: COM701, a potential first-in-class anti-PVRIG antibody being evaluated in the MAIA-ovarian randomized trial as maintenance monotherapy in relapsed platinum-sensitive ovarian cancer; rilvegostomig, a PD-1/TIGIT bispecific antibody derived from Compugen's COM902 program that is licensed to and being developed by AstraZeneca across 12 Phase 3 clinical trials; and GS-0321 (formerly COM503), a potential first-in-class anti-IL-18 binding protein antibody licensed to Gilead Sciences that is in a Phase 1 dose-escalation trial conducted by Compugen. The company generates revenue primarily from license agreement payments related to its Gilead partnership and is eligible for future milestone payments and royalties from both the AstraZeneca and Gilead agreements. Compugen's shares are dual-listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker CGEN. Updated Aug 3, 2026